3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
16
Uterine Cervical Neoplasms
5
Stomach Neoplasms
5
Lung Neoplasms
5
Carcinoma, Transitional Cell
5
Carcinoma, Hepatocellular
5
Squamous Cell Carcinoma of Head and Neck
4
Sarcoma
4
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Oropharyngeal Neoplasms
4
Esophageal Neoplasms
4
Cholangiocarcinoma
4
Urinary Bladder Neoplasms
3
Thyroid Neoplasms
3
Neuroendocrine Tumors
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Lymphoma, Large B-Cell, Diffuse
3
Anus Neoplasms
3
Testicular Neoplasms
2
Solid Tumor
2
Pheochromocytoma
2
Paraganglioma
2
Pancreatic Neoplasms
2
Neoplasms
2
Mouth Neoplasms
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Laryngeal Neoplasms
2
Interventions
pembrolizumab
3
Paclitaxel
3
Doxorubicin
3
durvalumab
2
Standard of Care
2
Nivolumab
2
Ipilimumab
2
Ifosfamide
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
sintilimab
1
selinexor
1
sarilumab
1
regorafenib
1
pexidartinib
1
pertuzumab
1
peginterferon alfa-2a
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
eribulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
Fluorodeoxyglucose F18
×
1 year
×
Clear all
No trials found.